智通财经网·2025-09-30 03:04Core Viewpoint - Rongchang Biopharma (09995) has seen a stock price increase of over 7%, currently trading at 118.8 HKD with a transaction volume of 476 million HKD, driven by significant developments in its product pipeline and research achievements [1] Group 1: Product Development - On September 30, the CDE website announced that Rongchang Biopharma's ophthalmic innovative drug, Ilifapru α (RC28), has been submitted for market approval for the treatment of Diabetic Macular Edema (DME) [1] - In August, Rongchang Biopharma entered into an agreement with Santen Pharmaceutical's wholly-owned subsidiary, Santen China, granting exclusive rights for the development, production, and commercialization of Ilifapru α in Greater China and several Southeast Asian countries, with a total transaction value of 1.295 billion CNY [1] Group 2: Research Achievements - Rongchang Biopharma has successfully had 11 original research results selected for presentation at the 2025 European Society for Medical Oncology (ESMO) annual meeting, scheduled from October 17 to 21 in Berlin, Germany [1] - The RC48-C016 phase III clinical study of Vidisichimab in combination therapy for first-line urothelial carcinoma has been selected for the latest breakthrough abstract (LBA), and the company will showcase data across multiple tumor types and treatment strategies, including 2 short oral presentations and 8 poster displays covering urothelial carcinoma, gastric cancer, and gynecological tumors [1]